Royalty Report: Drugs, Disease, Respiratory – Collection: 273401

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Disease
  • Respiratory
  • Assay
  • Proteins
  • Therapeutic
  • Delivery
  • Fibrosis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 273401

License Grant
Licensor, a non-profit organization, grants a worldwide, non-exclusive license, without the right to sublicense, to the Licensor Background Intellectual Property, and such Intellectual Property as may be conceived, developed or acquired by Licensor, for all uses and purposes by Licensee related to the Research Program and Research Plan and that may be necessary or useful for the development or exploitation of a Drug Product.

Licensee and/or its licensees and sublicensees shall have exclusive rights to manufacture, market, sell and distribute all Drug Products in the Territory.

License Property
Licensee shall use Licensor s Data Safety Monitoring Board and the Therapeutics Development Network (TDN), as feasible, in connection with its clinical trials involving cystic fibrosis (CF) patients.

Drug Product resulting from a Drug Product Candidate shall mean a finished dosage form which is approved by a regulatory authority for administration to patients as a pharmaceutical.

Field of Use
The Field shall mean the treatment of conditions or diseases in the cystic fibrosis field, asthma, chronic bronchitis and chronic obstructive pulmonary disease.

IPSCIO Record ID: 256291

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensee, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensor.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensee, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

For patentable inventions, Licensor grants to an exclusive, royalty free worldwide license to its rights in any Joint Invention and any invention made by made by any CFFT employee resulting from the Research Project to research, develop, manufacture, use, sell and import products.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

CFTR is the key protein associated with cystic fibrosis.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.

Cystic fibrosis (CF) is a life-threatening genetic disease that causes fatal lung infections and serious digestive complications. A mutation in the CFTR gene is one of the key factors that ultimately leads to the symptoms, complications and premature mortality in people with cystic fibrosis.

IPSCIO Record ID: 203566

License Grant
The parties entered into to a Research and Development Agreement dated March 10, 1997 relating to EPI-HNE4, an inhibitor of human neutrophil elastase.  The Parties now enter into this Agreement for thecommercialization of the results of the Research and Development Agreement.

Licensor grants the Swiss Licensee an exclusive license with the right to sublicense during the term of this Agreement, under the EPI-HNE Patent Rights, EPIHNE Technology, the cystic fibrosis or CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export CF Product in the Territory and to make or have made or to purchase or have purchased CF Product for such purposes.

Licensor grants exclusive license with the right to sublicense during the term of this Agreement, under the EPIHNE Patent Rights, EPI-HNE Technology, the applicable CF Know-How and CF Patent Rights, to develop, use, offer for sale, sell, have sold, import and export any Other Product in the Territory and to make or have made or to purchase or have purchased such Other Products for such purposes.

License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 204327

License Grant
Swiss Licensor grants to Licensee, under the cystic fibrosis or CF Know-How and the CF Patent Rights
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product in North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export CF Product outside of the Territory and outside of North America and to make or have made or to purchase or have purchased CF Product for such purposes;
– an exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export Other Products outside of the Territory and to make or have made or to purchase or have purchased Other Products for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export therapeutic products outside of the Field of Use and to make or have made or to purchase or have purchased therapeutic products outside the Field of Use for such purposes;
– a worldwide exclusive license and sublicense, to develop, use, offer for sale, sell, have sold, import and export non-therapeutic products and to make or have made or to purchase or have purchased non-therapeutic products for such purposes.
License Property
The EPI-HNE Technology shall mean molecules, including EPI-HNE4, recombinant strains that produce EPI-HNE4 and methods of purifying EPI-HNE4 from recombinant organisms, and other protein molecules with anti-neutrophil elastase activity as described in the EPI-HNE Patent Rights.

The Product is for cystic fibrosis.

Field of Use
The field means human therapeutic uses solely for the treatment of cystic fibrosis, acute respiratory distress syndrome ('ARDS'), and chronic obstructive pulmonary diseases (COPD), such as emphysema and chronic bronchitis.

IPSCIO Record ID: 263060

License Grant
In this Agreement, the Licensee expanded the scope of the license agreement with the Licensor, who prior to 2015 was Parent of Licensee, for rights to develop and commercialize pulsed nitric oxide for idiopathic pulmonary fibrosis to include patients with Pulmonary Fibrosis (PH-PF).
License Property
The Licensor manufactures and markets pharmaceutical drugs and devices, based on proprietary pulsatile nitric oxide delivery.

INOpulse program is an extension of the technology used in hospitals to deliver continuous-flow inhaled nitric oxide.

Field of Use
The clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases,  expanded the scope of the license from PH-IPF to PH in patients with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung disease, with a royalty on net sales of any commercial products for PH-PF.  Pulmonary fibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred.

IPSCIO Record ID: 257285

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensor, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensee.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensor, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

With the Interruption License, Licensor grants with respect to the Research Project the Interruption License, which shall become effective solely upon written notice given by Licensee in the event of an Interruption an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Research Project Technology and the Licensor Background Technology necessary to develop, manufacture, have manufactured. use, sell, offer to sell and import Products in the Field.

In the event that Licensor transfers all of or certain of its rights and obligations to develop and commercialize a Product in the Field at any time, the Third Party to which Licensor transfers all or certain rights and obligations to develop and commercialize the Product in the Field shall be subject to the obligations of the Interruption License.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.
Cystic fibrosis (CF) is an inherited disease that causes thickened mucus to form in the lungs, pancreas and other organs. In the lungs, this mucus blocks the airways, causing lung damage and making it hard to breathe.
Pulmonary Disease or lung disease is any problem in the lungs that prevents the lungs from working properly.

IPSCIO Record ID: 118195

License Grant
The parties entered into an agreement to obtain worldwide rights to TOBI.
License Property
TOBI, is an inhaled antibiotic that was developed to treat pseudomonal lung infections. TOBI(R) (tobramycin solution for inhalation) was initially tested and approved for cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.  TOBI also is being used by non-CF patients with similar respiratory infections.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 213206

License Grant
The Irish Licensor grants the Licensee a worldwide license for the use of Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease.
License Property
Trelegy Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD), a group of diseases that includes chronic bronchitis and emphysema.

COPD is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 262807

License Grant
The Company entered into an agreement with a manufacturer of the nebulizer for the use to administer Molgradex.
License Property
Molgradex (an inhalation formulation of recombinant human GM-CSF for the treatment of aPAP) for the treatment of severe pulmonary conditions.  Molgradex is administered to the lungs using the investigational eFlow® Nebulizer System.

Molgradex, is a sterile nebulizer solution in a vial containing 300 µg of molgramostim, designed to be administered once daily by inhalation via a high efficiency Investigational eFlow Nebulizer System. The PARI eFlow Nebulizer system for use with investigational drug products is a reusable electronic inhalation system that has been optimized for administration of Molgradex.

“aPAP” – autoimmune pulmonary alveolar proteinosis

“CF” –  nontuberculous mycobacterial (“NTM”) lung infection n individuals living with cystic fibrosis

AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (“MRSA”) lung infection in individuals living with CF.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 278002

License Grant
The agreement is for Phase 2b Clinical Trial for lenabasum, and commercialization.
License Property
Lenabasum is an oral anti-inflammatory drug in adults with cystic fibrosis.
Field of Use
The field of use is for patients with cystic fibrosis.  Licensee is a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.